Tengsheng Pharmaceutical -B (02137.HK) announces its interim financial results. The company's attributable loss is approximately 148 million yuan, a decrease of 47.22% year-on-year.

Wisdom Financial News APP reports that Tengsheng Boyao-B (02137.HK) announced its mid-term performance for 2025. Other income was RMB 28.10 million, a decrease of 60.4% year-on-year. Research and development expenditure was RMB 117 million, a decrease of 7.3% year-on-year. The loss for the period was approximately RMB 149 million, a decrease of 47.5% year-on-year. The loss attributable to owners of the company was approximately RMB 148 million, a decrease of 47.22% year-on-year.